IP Library Granted Patent US 12,460,131
Granted Patent B2
US 12,460,131 · App. 17/196,994 · Granted Nov 4, 2025

Surfactants for electronics products

Inventor: Edward Asirvatham (Chatham, NJ)
Assignee: AdvanSix Resins & Chemicals LLC
C09K13/08C07C229/12C07C309/14C09K13/00C23F1/38G03F7/327
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,460,131
App. No.
17/196,994
Granted
Nov 4, 2025
Kind
B2
Abstract

Pre-texturing agents, etchants, and photoresist stripping agents may be formulated to include one or more surfactants, from one or more surfactant classes, such as derivatives of amino acids that have surface-active properties.

Claims (50)

1 . A formulation for a pre-texturing agent, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

n is an integer from 2 to 5;

m is an integer from 12 to 18; which identifies the number of carbon atoms in a straight alkyl chain;

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of chloride, bromide, iodide, and hydroxide; and

at least one of one or more solvents and one or more defoaming agents.

2 . The formulation of claim 1 , further comprising one or more acids.

3 . The formulation of claim 1 , further comprising one or more bases.

4 . The formulation of claim 1 , further comprising one or more chelating agents.

5 . The formulation according to claim 1 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

6-(dodecyloxy)-N,N-dimethyl-6-oxohexan-1-aminium chloride, having the following formula:

6-(dodecyloxy)-6-oxohexan-1-aminium chloride, having the following formula:

and combinations thereof.

6 . A formulation for an etchant, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

n is an integer from 2 to 5;

m is an integer from 12 to 18 which identifies the number of carbon atoms in a straight alkyl chain;

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of chloride, bromide, iodide, and hydroxide; and

hydrofluoric acid (1f).

7 . The formulation of claim 6 , further comprising one or more oxidizing agents.

8 . The formulation of claim 6 , further comprising one or more complexing agents.

9 . The formulation according to claim 6 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

6-(dodecyloxy)-N,N-dimethyl-6-oxohexan-1-aminium chloride, having the following formula:

6-(dodecyloxy)-6-oxohexan-1-aminium chloride, having the following formula:

and combinations thereof.

10 . A formulation for a photoresist stripping formulation, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

n is an integer from 2 to 5;

m is an integer from 12 to 18 which identifies the number of carbon atoms in a straight alkyl chain;

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, carbonyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of chloride, bromide, iodide, and hydroxide; and

an alkanolamine.

11 . The formulation of claim 10 , further comprising a sulfoxide.

12 . The formulation of claim 10 , further comprising a sulfone.

13 . The formulation of claim 10 , further comprising a glycol ether.

14 . The formulation according to claim 10 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

6-(dodecyloxy)-N,N-dimethyl-6-oxohexan-1-aminium chloride, having the following formula:

6-(dodecyloxy)-6-oxohexan-1-aminium chloride, having the following formula:

and combinations thereof.

15 . The formulation of claim 1 , wherein n is 5.

16 . The formulation of claim 6 , wherein n is 5.

17 . The formulation of claim 10 , wherein n is 5.

Assignments (2)
SECURITY INTEREST Recorded Oct 27, 2021
From: ADVANSIX INC.; ADVANSIX RESINS & CHEMICALS LLC
To: TRUIST BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 057940/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: ASIRVATHAM, EDWARD
To: ADVANSIX RESINS & CHEMICALS LLC
Reel/Frame 056334/0336 →
Continuity (2)
Provisional Application 62988175 · Mar 11, 2020
Related Publication 20210292647A1 · Sep 23, 2021
References Cited (85)
US 3213500A · Thompson · 1965 [cited by applicant]
US 3704486A · Blacklock · 1972 [cited by applicant]
US 4276460A · Haesly et al. · 1981 [cited by applicant]
US 4297769A · Coules · 1981 [cited by applicant]
US 4502193A · Harmon et al. · 1985 [cited by applicant]
US 4664458A · Worth · 1987 [cited by applicant]
US 5060100A · Mihara et al. · 1991 [cited by applicant]
US 5580203A · Read et al. · 1996 [cited by applicant]
US 5706559A · Oliver et al. · 1998 [cited by applicant]
US 5798095A · Racky · 1998 [cited by applicant]
US 5958894A · Heath et al. · 1999 [cited by applicant]
US 5972323A · Lang et al. · 1999 [cited by applicant]
US 6114757A · Delprete · 2000 [cited by applicant]
US 6304986B1 · Ma et al. · 2001 [cited by applicant]
US 6501030B1 · Parizi et al. · 2002 [cited by applicant]
US 6702592B1 · Harden et al. · 2004 [cited by applicant]
US 7646556B1 · Kose et al. · 2010 [cited by applicant]
US 7653847B1 · Liikanen et al. · 2010 [cited by applicant]
US 7768736B2 · Belmont et al. · 2010 [cited by applicant]
US 8599507B2 · Sanvido et al. · 2013 [cited by applicant]
US 8964320B1 · Hu et al. · 2015 [cited by applicant]
US 9142246B1 · Trantham et al. · 2015 [cited by applicant]
US 9484059B2 · Lim et al. · 2016 [cited by applicant]
US 9552846B1 · Lim · 2017 [cited by applicant]
US 20030081357A1 · Hong et al. · 2003 [cited by applicant]
US 20080259100A1 · Rengaswamy et al. · 2008 [cited by applicant]
US 20100119468A1 · Garcia Castro · 2010 [cited by examiner]
US 20170079898A1 · Fevola · 2017 [cited by examiner]
US 20170260449A1 · Barnes et al. · 2017 [cited by applicant]
US 20190010426A1 · Scialla · 2019 [cited by examiner]
US 20210229053A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230100A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230106A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230107A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230108A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210283030A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210284896A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210284936A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210289776A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210290765A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210292583A1 · Asirvatham et al. · 2021 [cited by applicant]
CA 2647330C · 2012 [cited by examiner]
CA 3034712A1 · 2018 [cited by examiner]
CN 104145324A · 2014 [cited by applicant]
CN 105802600A · 2016 [cited by applicant]
CN 108024935A · 2018 [cited by applicant]
DE 3939746A1 · 1991 [cited by applicant]
DE 29622184U1 · 1997 [cited by applicant]
EP 0135217A1 · 1985 [cited by examiner]
EP 0638236A1 · 1995 [cited by applicant]
EP 0826661A2 · 1998 [cited by applicant]
GB 2204740A · 1988 [cited by applicant]
GB 2311033A · 1997 [cited by applicant]
JP 61278341A · 1986 [cited by applicant]
JP 04349284A · 1992 [cited by applicant]
JP 08007556A · 1996 [cited by applicant]
JP 09266021A · 1997 [cited by applicant]
JP 11233910A · 1999 [cited by applicant]
JP 2006294170A · 2006 [cited by applicant]
JP 2017195029A · 2017 [cited by applicant]
WO 9845233A2 · 1998 [cited by applicant]
WO 0368377A1 · 2003 [cited by applicant]
WO 2012061093A1 · 2012 [cited by applicant]
WO 2017012087A1 · 2017 [cited by applicant]
WO 2017048555A1 · 2017 [cited by applicant]
WO 2017199921A1 · 2017 [cited by applicant]
WO 2018115191A1 · 2018 [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014440, mailed on Apr. 30, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014444, mailed on Apr. 26, 2021, 12 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014445, mailed on Apr. 26, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014447, mailed on Apr. 30, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014457, mailed on Apr. 30, 2021, 8 pages. [cited by applicant]
Novotny et al., “Transkarbams as transdermal permeation enhancers: effects of ester position and ammonium carbamate formation”, Bioorganic & medicinal chemistry letters, vol. 20, No. 9, May 1, 2010, pp. 2726-2728. [cited by applicant]
Yasa et al., “Synthesis, characterization, antimicrobial and biofilm inhibitory activities of new N-oxide esters”, Medicinal Chemistry Research, vol. 26, No. 8, Apr. 3, 2017, pp. 1689-1696. [cited by applicant]
Hrabálek et al., “Esters of omega-amino acids as flexible penetration enhancers”, Pharmazie, vol. 49, No. 5, May 1994, pp. 325-328. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/021565, mailed on Jun. 18, 2021, 13 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/021569, mailed on May 17, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21571, mailed on Jul. 9, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21574, mailed on Jul. 1, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21595, mailed on Jul. 30, 2021, 15 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21596, mailed on Jun. 22, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21597, mailed on Aug. 9, 2021, 11 pages. [cited by applicant]
Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US21/21595, mailed on Jun. 9, 2021, 9 pages. [cited by applicant]
Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US21/21597, mailed on Jun. 17, 2021, 7 pages. [cited by applicant]
Kerry P. Mahon et al: “Combinatorial Approach to Determine Functional Group Effects on Lipidoid-Mediated si RNA Delivery”, Bioconjugate Chemistry, vol. 21, No. 8, Aug. 18, 2010 (Aug. 18, 2010), pp. 1448-1454. [cited by applicant]